MIST News & Events

Milestone Pharmaceuticals announced that cardamyst nasal spray, its first commercial product, is now available through U.S. retail pharmacies. Cardamyst is a prescription medication indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm in adults. Implementation of a rapid commercialization plan is underway with a national sales force to be deployed in mid-February 2026.

Milestone Pharmaceuticals announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA, seeking the approval of etripamil nasal spray, developed to be the first rapid, reliable option in the treatment of paroxysmal supraventricular tachycardia, PSVT, outside of the healthcare setting. Etripamil, which has the conditionally approved brand name TACHYMIST in Europe, is an investigational, novel calcium channel blocker delivered via a nasal spray by the patient for the potential treatment of PSVT and other cardiac arrhythmias. A decision on approval is expected by the first quarter of 2027.